Cardiac imaging software provider Heartflow, Inc. (HTFL.US) announced its IPO terms last Friday. The Mountain View, California-based company plans to offer 12.5 million shares at a price range of $15 to $17 per share, aiming to raise $200 million. Based on the midpoint of the proposed offering price range, Heartflow's fully diluted market capitalization would reach $1.4 billion.

Heartflow provides a non-invasive solution for diagnosing and managing coronary artery disease (CAD). As of March 31, 2025, the Heartflow platform has been used to evaluate coronary artery disease in over 400,000 patients, with 132,000 patients evaluated in 2024 alone.

This innovative platform utilizes artificial intelligence and advanced computational fluid dynamics technology to build personalized 3D models of patients' hearts and provides actionable insights on blood flow, vessel stenosis, plaque volume, and plaque composition.

Founded in 2007, Heartflow reported revenue of $136 million for the 12 months ended March 31, 2025. The company plans to list on NASDAQ under the ticker symbol "HTFL." JPMorgan, Morgan Stanley, and Piper Sandler serve as joint underwriters for the transaction. The company is expected to finalize its offering price during the week of August 4.